Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Millennium Management LLC

Millennium Management LLC lessened its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 76.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 215,531 shares of the biotechnology company’s stock after selling 718,857 shares during the quarter. Millennium Management LLC owned 0.14% of Heron Therapeutics worth $330,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. New York State Common Retirement Fund boosted its holdings in Heron Therapeutics by 3.2% in the fourth quarter. New York State Common Retirement Fund now owns 1,321,006 shares of the biotechnology company’s stock worth $2,021,000 after acquiring an additional 41,062 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Heron Therapeutics by 0.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company’s stock worth $1,692,000 after purchasing an additional 9,418 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Heron Therapeutics by 9.5% in the fourth quarter. Bank of America Corp DE now owns 1,046,790 shares of the biotechnology company’s stock worth $1,602,000 after purchasing an additional 90,862 shares during the last quarter. Northern Trust Corp raised its stake in shares of Heron Therapeutics by 2.2% in the fourth quarter. Northern Trust Corp now owns 1,011,756 shares of the biotechnology company’s stock worth $1,548,000 after purchasing an additional 21,769 shares during the last quarter. Finally, CM Management LLC raised its stake in shares of Heron Therapeutics by 40.0% in the fourth quarter. CM Management LLC now owns 700,000 shares of the biotechnology company’s stock worth $1,071,000 after purchasing an additional 200,000 shares during the last quarter. Institutional investors and hedge funds own 80.01% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Needham & Company LLC restated a “buy” rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research note on Friday, April 11th. HC Wainwright started coverage on Heron Therapeutics in a research report on Monday. They set a “buy” rating and a $6.00 price target for the company. Finally, Wall Street Zen upgraded Heron Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 6th.

Heron Therapeutics Stock Performance

Shares of HRTX stock opened at $2.12 on Wednesday. The stock has a 50 day moving average of $2.01 and a 200 day moving average of $1.88. The stock has a market cap of $323.44 million, a P/E ratio of -11.78 and a beta of 1.16. Heron Therapeutics, Inc. has a twelve month low of $1.04 and a twelve month high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.02. The company had revenue of $38.90 million for the quarter, compared to analysts’ expectations of $37.08 million. On average, research analysts predict that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.